Table 3.
IBD Treatment Management |
---|
Withhold immunomodulation during active cancer therapy |
Withhold thiopurines if bone marrow suppression is expected from the planned chemotherapy |
Considerer avoiding immunomodulation in the first 2 years after cancer |
Avoid combination therapy in cancer patients |
Avoid JAK inhibitors in cancer patients |